ESPE Abstracts

Introduction: Currently, there is no diagnostic gold standard for growth hormone deficiency (GHD). The diagnosis of GHD is based on the current consensus guidelines, which state that an inadequate GH level of 7 ng/mL during two growth hormone stimulation tests (GHSTs) is indicative of GHD. The primary objectives of this study were to assess the sensitivity and specificity of low IGF-1 levels in combination with a single insulin tolerance test (ITT) for diagnos...

Introduction: Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although there are numerous GnRH agonist variants available, there is limited research comparing the timing of menarche in girls treated with monthly (3.75 mg) versus 3-monthly (11.25 mg) Leuprolide acetate. The objective of this study was to evaluate the timing of menarche after the administration of monthly and 3-monthly Leuprolide acetate...

Introduction: Anogenital distance (AGD) is a useful marker of prenatal androgen exposure and a tool for assessment of differences of sex development. Normative data on AGD ranges for local references should be established as standards for comparison in clinical practice, but there is a paucity of data among newborns in Thailand.Aim: To provide the sex-specific ranges for AGD in Thai full-term newborns.<p class="abste...

Background: Kisspeptin and Delta-like 1 homolog (DLK1) are neuropeptides that regulate pubertal timing by activating and inhibiting the hypothalamic-pituitary-gonadal axis; consequently, measuring these biomarkers could potentially distinguish central precocious puberty (CPP) from premature thelarche (PT) girls and monitor CPP treatment.Objectives: To compare baseline serum kisspeptin and DLK1 levels in girls with CPP at...